DK1618195T3 - Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA) - Google Patents
Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)Info
- Publication number
- DK1618195T3 DK1618195T3 DK04730318T DK04730318T DK1618195T3 DK 1618195 T3 DK1618195 T3 DK 1618195T3 DK 04730318 T DK04730318 T DK 04730318T DK 04730318 T DK04730318 T DK 04730318T DK 1618195 T3 DK1618195 T3 DK 1618195T3
- Authority
- DK
- Denmark
- Prior art keywords
- myc
- nucleic acids
- peptide nucleic
- pna
- antigen peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000860A ITMI20030860A1 (it) | 2003-04-29 | 2003-04-29 | Metodo per l'inibizione selettiva del gene n-myc |
PCT/IB2004/001297 WO2004096826A2 (en) | 2003-04-29 | 2004-04-29 | Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1618195T3 true DK1618195T3 (da) | 2008-07-07 |
Family
ID=33398059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04730318T DK1618195T3 (da) | 2003-04-29 | 2004-04-29 | Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA) |
Country Status (12)
Country | Link |
---|---|
US (1) | US7947657B2 (de) |
EP (1) | EP1618195B1 (de) |
JP (1) | JP4719670B2 (de) |
AT (1) | ATE389017T1 (de) |
CA (1) | CA2522890C (de) |
DE (1) | DE602004012404T2 (de) |
DK (1) | DK1618195T3 (de) |
ES (1) | ES2303636T3 (de) |
IT (1) | ITMI20030860A1 (de) |
PL (1) | PL1618195T3 (de) |
PT (1) | PT1618195E (de) |
WO (1) | WO2004096826A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06012076A (es) | 2004-04-20 | 2007-01-25 | Nastech Pharm Co | Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero. |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
EP1970075B1 (de) * | 2005-12-26 | 2012-04-11 | Riken | THERAPEUTISCHES MITTEL FÜR NEUROBLASTOM TARGETING ARID3b |
US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
ITMI20120275A1 (it) | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
US11827884B2 (en) | 2017-05-15 | 2023-11-28 | University Of Florida Research Foundation, Incorporated | Core master regulators of glioblastoma stem cells |
TW202112394A (zh) * | 2019-06-06 | 2021-04-01 | 日商電化股份有限公司 | 以肽核酸為基礎之佐劑 |
-
2003
- 2003-04-29 IT IT000860A patent/ITMI20030860A1/it unknown
-
2004
- 2004-04-29 DE DE602004012404T patent/DE602004012404T2/de not_active Expired - Lifetime
- 2004-04-29 CA CA2522890A patent/CA2522890C/en not_active Expired - Lifetime
- 2004-04-29 PL PL04730318T patent/PL1618195T3/pl unknown
- 2004-04-29 EP EP04730318A patent/EP1618195B1/de not_active Expired - Lifetime
- 2004-04-29 DK DK04730318T patent/DK1618195T3/da active
- 2004-04-29 JP JP2006506541A patent/JP4719670B2/ja not_active Expired - Lifetime
- 2004-04-29 US US10/554,291 patent/US7947657B2/en active Active
- 2004-04-29 WO PCT/IB2004/001297 patent/WO2004096826A2/en active IP Right Grant
- 2004-04-29 ES ES04730318T patent/ES2303636T3/es not_active Expired - Lifetime
- 2004-04-29 AT AT04730318T patent/ATE389017T1/de active
- 2004-04-29 PT PT04730318T patent/PT1618195E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
ES2303636T3 (es) | 2008-08-16 |
PL1618195T3 (pl) | 2008-09-30 |
DE602004012404D1 (de) | 2008-04-24 |
WO2004096826A2 (en) | 2004-11-11 |
US7947657B2 (en) | 2011-05-24 |
EP1618195A2 (de) | 2006-01-25 |
CA2522890A1 (en) | 2004-11-11 |
US20070020632A1 (en) | 2007-01-25 |
ATE389017T1 (de) | 2008-03-15 |
JP4719670B2 (ja) | 2011-07-06 |
WO2004096826A3 (en) | 2005-05-26 |
DE602004012404T2 (de) | 2009-03-26 |
JP2006525010A (ja) | 2006-11-09 |
CA2522890C (en) | 2013-07-02 |
PT1618195E (pt) | 2008-06-24 |
EP1618195B1 (de) | 2008-03-12 |
ITMI20030860A1 (it) | 2004-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
IN2015KN00290A (de) | ||
DE60335637D1 (de) | Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren | |
WO2005086835A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
DE60332363D1 (de) | Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen | |
DK1618195T3 (da) | Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA) | |
ATE521702T1 (de) | Krebsantigene und deren nutzung | |
MXPA05006034A (es) | Proteina de duplicacion. | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
HUP0102614A2 (hu) | Az angiogenezis módosítására alkalmas, SRC tirozin kinázt hasznosító eljárások és kompozíciók | |
EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака | |
WO2005117974A3 (en) | Cancer treatment method by inhibiting mage gene expression or function | |
WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system | |
DE60128950D1 (de) | Proteine aus yaba monkey tumor virus mit modulatorischer aktivität | |
ATE315406T1 (de) | Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen | |
ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung | |
ATE352632T1 (de) | Dna-expressionskonstrukt zur multiplen genexpression | |
TNSN06265A1 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
DK1537210T3 (da) | Decoy-oligonukleotid-inhibering af CD40-ekspression | |
DE50015171D1 (de) | Rna polymerase i transkriptionsfaktor tif-ia | |
WO2005094415A3 (en) | Recombinant vectors and methods for inducing an immune response |